<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02981329</url>
  </required_header>
  <id_info>
    <org_study_id>H-38457 Metformin</org_study_id>
    <nct_id>NCT02981329</nct_id>
  </id_info>
  <brief_title>Fetal Hemoglobin Induction Treatment Metformin</brief_title>
  <acronym>FITMet</acronym>
  <official_title>Use of Metformin as a Fetal Hemoglobin Inducer in Patients With Hemoglobinopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether metformin is effective in the treatment for
      sickle cell anemia (SCA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose escalation, pilot study for subjects with sickle cell anemia (SCA) disease to
      determine if metformin has a beneficial effect on the treatment and quality of life of SCA
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2017</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fetal Hemoglobin (HbF) Percentage (SCA) or Change in Total Hemoglobin (Hb)</measure>
    <time_frame>1 Year</time_frame>
    <description>Change in HbF percentage (%) or total Hb will be assessed by comparing baseline values to on treatment values per subject and will be summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Laboratory Values</measure>
    <time_frame>1 Year</time_frame>
    <description>Evaluation and percentage of change in numeric values of total blood count, liver function, HbF levels, whole blood viscosity, and percent dense red blood cells will be evaluated per subject over the duration of the study and summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on Quality of Life</measure>
    <time_frame>1 Year</time_frame>
    <description>Evaluation of subject's change in quality of life will be assessed per subject per study questionnaire(s) over the duration of the study and summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of Hemoglobin Response</measure>
    <time_frame>1 Year</time_frame>
    <description>Evaluation of hematological variability of fetal hemoglobin induction will be assessed per subject per genetic analysis and summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of RNA Sequencing</measure>
    <time_frame>1 Year</time_frame>
    <description>Evaluate expression changes in paired samples collected before and on metformin through RNA sequencing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Sickle Cell Anemia</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Hemoglobin Disorder</condition>
  <arm_group>
    <arm_group_label>Group A: Hydroxyurea + Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are currently taking Hydroxyurea as part of standard of care and have sickle cell anemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Metformin (Group B has closed to enrollment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are not taking Hydroxyurea as part of standard of care and have sickle cell anemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.</description>
    <arm_group_label>Group A: Hydroxyurea + Metformin</arm_group_label>
    <arm_group_label>Group B: Metformin (Group B has closed to enrollment)</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Riomet,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Questionnaires will be completed to assess the impact quality of life</description>
    <arm_group_label>Group A: Hydroxyurea + Metformin</arm_group_label>
    <arm_group_label>Group B: Metformin (Group B has closed to enrollment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of sickle cell anemia

          2. Age greater than or equal to 10 and less than or equal to 60 years of age.

          3. If on hydroxyurea, fetal hemoglobin less than 20% at a stable dose (mg/kg) determined
             by the primary hematology provider over at least four months.

          4. Creatinine less than or equal to 1.4 mg/dL and estimated glomerular filtration rate
             greater than 45 ml/min/1.73 m2

          5. Liver function tests (specifically ALT and conjugated bilirubin) less than or equal to
             4 times upper limits of normal.

        Exclusion Criteria:

          1. Failure to meet inclusion criteria

          2. Simple or chronic red blood cell transfusion therapy in the last 3 months OR a HbA
             level greater than 5% in SCA patients

          3. Refusal to use medically effective birth control if female and sexually active.

          4. If on hydroxyurea, not at stable dose of hydroxyurea for a minimum of 4 months
             (temporary exclusion).

          5. Creatinine greater than 1.4mg/dL

          6. Liver function tests (ALT and conjugated bilirubin) greater than 4 times upper limits
             of normal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivien Sheehan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vivien Sheehan, MD</last_name>
    <phone>832-824-4459</phone>
    <email>vxsheeha@texaschildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chukwuma Kalu</last_name>
    <email>cokalu@texaschildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivien Sheehan, MD</last_name>
      <phone>832-824-4459</phone>
      <email>vxsheeha@texaschildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Bodgan Dinu</last_name>
      <email>brdinu@texaschildrens.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harinder Juneja, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Vivien Sheehan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Sickle Cell Anemia</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Hemoglobinopathies</keyword>
  <keyword>Hemoglobin Disorder</keyword>
  <keyword>Blood Disease</keyword>
  <keyword>Hemoglobin Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The leftover blood samples for genetic analysis will be banked indefinitely for future ancillary studies. Investigator who desires access to these samples must present their research idea prior to receiving access to the samples. The samples will be shared with researchers affiliated with Texas Children's Hospital, Baylor College of Medicine and/or other hematology collaborators for future studies associated with hematologic diseases and drugs used to treat such diseases. The recipient investigators are required to provide proof of IRB approval or exemption as per local IRB guidelines before the sample can be released for research purposes. After receipt of IRB approval, coded samples will be distributed to the recipient investigator.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

